Drug Profile
Research programme: peptidomimetic renin inhibitors - Novartis
Alternative Names: CGP-54061Latest Information Update: 26 May 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class Small molecules
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension